Cargando…
Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer
BACKGROUND: There has been remarkable progress in systemic chemotherapy for metastatic colorectal cancer due to the widespread use of irinotecan, oxaliplatin, anti-vascular endothelial growth factor antibody, and anti-epidermal growth factor receptor antibody. It is important to continue treatment w...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944910/ https://www.ncbi.nlm.nih.gov/pubmed/27468238 http://dx.doi.org/10.2147/OTT.S104140 |
_version_ | 1782442829179518976 |
---|---|
author | Kotaka, Masahito Ikeda, Fusao Tsujie, Masaki Yoshioka, Shinichi Nakamoto, Yoshihiko Ishii, Takaaki Kyogoku, Takahisa Kato, Takeshi Tsuji, Akihito Kobayashi, Michiya |
author_facet | Kotaka, Masahito Ikeda, Fusao Tsujie, Masaki Yoshioka, Shinichi Nakamoto, Yoshihiko Ishii, Takaaki Kyogoku, Takahisa Kato, Takeshi Tsuji, Akihito Kobayashi, Michiya |
author_sort | Kotaka, Masahito |
collection | PubMed |
description | BACKGROUND: There has been remarkable progress in systemic chemotherapy for metastatic colorectal cancer due to the widespread use of irinotecan, oxaliplatin, anti-vascular endothelial growth factor antibody, and anti-epidermal growth factor receptor antibody. It is important to continue treatment with the optimal combination of these drugs and prolong progression-free survival (PFS) to improve overall survival (OS). We conducted a prospective observational cohort study of 40 patients treated with XELOX plus bevacizumab for previously untreated metastatic colorectal cancer to investigate treatment continuity. PATIENTS AND METHODS: Eligibility criteria were as follows: 1) histologically confirmed metastatic colorectal cancer; 2) lesions evaluable by imaging; 3) previously untreated; 4) suitable condition to receive XELOX plus bevacizumab; and 5) written informed consent. Outcomes were treatment continuity, overall response rate, resection rate, liver resection rate, time to treatment failure, PFS, and OS. Forty patients were enrolled and followed up for 2 years. RESULTS: Between July 2010 and June 2012, 40 patients were enrolled. The median number of treatment cycles was 7.5, and the reasons for discontinuation of treatment were as follows: complete response (five patients), resection (ten patients), progression (15 patients), adverse events (seven patients), and patient refusal (three patients). The overall response rate was 57.5%, resection rate was 25%, and liver resection rate was 15%. After a median follow-up of 31.4 months, the median time to treatment failure, PFS, and OS were 5.3, 13.3, and 38.9 months, respectively. CONCLUSION: Although the median time to treatment failure was 5.3 months, the median PFS and OS were prolonged to 13.3 and 38.9 months, respectively. This may have resulted from the chemotherapy-free interval due to complete response in five patients and resection in ten patients. |
format | Online Article Text |
id | pubmed-4944910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49449102016-07-27 Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer Kotaka, Masahito Ikeda, Fusao Tsujie, Masaki Yoshioka, Shinichi Nakamoto, Yoshihiko Ishii, Takaaki Kyogoku, Takahisa Kato, Takeshi Tsuji, Akihito Kobayashi, Michiya Onco Targets Ther Original Research BACKGROUND: There has been remarkable progress in systemic chemotherapy for metastatic colorectal cancer due to the widespread use of irinotecan, oxaliplatin, anti-vascular endothelial growth factor antibody, and anti-epidermal growth factor receptor antibody. It is important to continue treatment with the optimal combination of these drugs and prolong progression-free survival (PFS) to improve overall survival (OS). We conducted a prospective observational cohort study of 40 patients treated with XELOX plus bevacizumab for previously untreated metastatic colorectal cancer to investigate treatment continuity. PATIENTS AND METHODS: Eligibility criteria were as follows: 1) histologically confirmed metastatic colorectal cancer; 2) lesions evaluable by imaging; 3) previously untreated; 4) suitable condition to receive XELOX plus bevacizumab; and 5) written informed consent. Outcomes were treatment continuity, overall response rate, resection rate, liver resection rate, time to treatment failure, PFS, and OS. Forty patients were enrolled and followed up for 2 years. RESULTS: Between July 2010 and June 2012, 40 patients were enrolled. The median number of treatment cycles was 7.5, and the reasons for discontinuation of treatment were as follows: complete response (five patients), resection (ten patients), progression (15 patients), adverse events (seven patients), and patient refusal (three patients). The overall response rate was 57.5%, resection rate was 25%, and liver resection rate was 15%. After a median follow-up of 31.4 months, the median time to treatment failure, PFS, and OS were 5.3, 13.3, and 38.9 months, respectively. CONCLUSION: Although the median time to treatment failure was 5.3 months, the median PFS and OS were prolonged to 13.3 and 38.9 months, respectively. This may have resulted from the chemotherapy-free interval due to complete response in five patients and resection in ten patients. Dove Medical Press 2016-07-07 /pmc/articles/PMC4944910/ /pubmed/27468238 http://dx.doi.org/10.2147/OTT.S104140 Text en © 2016 Kotaka et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Kotaka, Masahito Ikeda, Fusao Tsujie, Masaki Yoshioka, Shinichi Nakamoto, Yoshihiko Ishii, Takaaki Kyogoku, Takahisa Kato, Takeshi Tsuji, Akihito Kobayashi, Michiya Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer |
title | Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer |
title_full | Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer |
title_fullStr | Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer |
title_full_unstemmed | Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer |
title_short | Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer |
title_sort | observational cohort study focused on treatment continuity of patients administered xelox plus bevacizumab for previously untreated metastatic colorectal cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944910/ https://www.ncbi.nlm.nih.gov/pubmed/27468238 http://dx.doi.org/10.2147/OTT.S104140 |
work_keys_str_mv | AT kotakamasahito observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer AT ikedafusao observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer AT tsujiemasaki observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer AT yoshiokashinichi observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer AT nakamotoyoshihiko observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer AT ishiitakaaki observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer AT kyogokutakahisa observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer AT katotakeshi observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer AT tsujiakihito observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer AT kobayashimichiya observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer |